Global Primary Hyperoxaluria Drug

Primary Hyperoxaluria Drug Comprehensive Study by Type (ALLN-230, DCR-PHXC, ALN-GO1, Others), Application (Hospital, Clinic, Others), Drug types (Primary hyperoxaluria type III (PH III), Primary hyperoxaluria type II (PH II), Primary hyperoxaluria type I (PH I)) Players and Region - Global Market Outlook to 2026

Primary Hyperoxaluria Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Primary Hyperoxaluria Drug Market Scope?
Primary hyperoxaluria type 1 (PH1) is an inherited autosomal recessive disorder that manifests itself in childhood and adolescence. Several defects in the enzyme alanine-glyoxylate aminotransferase cause an increase in oxalate production in the liver, which is excreted in the urine (hyperoxaluria). It causes recurrent kidney stones, renal calcification (nephrocalcinosis), kidney injury, and even kidney failure; many of these patients require dialysis before reaching adulthood. The rising prevalence of primary hyperoxaluria is driving up demand for primary hyperoxaluria drugs all over the world. It is estimated that 1 in 58,000 people worldwide will be affected. Type 1 is the most common, accounting for the majority of cases.

The Primary Hyperoxaluria Drug market study is being classified by Type (ALLN-230, DCR-PHXC, ALN-GO1 and Others), by Application (Hospital, Clinic and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Primary Hyperoxaluria Drug market throughout the predicted period.

Allena Pharmaceuticals Inc (United States), Alnylam Pharmaceuticals Inc (United States), Dicerna Pharmaceuticals Inc (United States), Intellia Therapeutics Inc (United States) and OxThera AB (Sweden) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Primary Hyperoxaluria Drug market by Type, Application and Region.

On the basis of geography, the market of Primary Hyperoxaluria Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • Increasing investment in research & development

Market Drivers
  • Rising awareness and increased diagnostic facilities

Opportunities
  • Demand for primary hyperoxaluria drugs is expected to be triggered in emerging economies such as China and India

Restraints
  • The adverse effect of the Primary Hyperoxaluria Drug

Challenges
  • Low presence of market players


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Primary Hyperoxaluria Drug Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • ALLN-230
  • DCR-PHXC
  • ALN-GO1
  • Others
By Application
  • Hospital
  • Clinic
  • Others
By Drug types
  • Primary hyperoxaluria type III (PH III)
  • Primary hyperoxaluria type II (PH II)
  • Primary hyperoxaluria type I (PH I)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising awareness and increased diagnostic facilities
    • 3.3. Market Challenges
      • 3.3.1. Low presence of market players
    • 3.4. Market Trends
      • 3.4.1. Increasing investment in research & development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Primary Hyperoxaluria Drug, by Type, Application, Drug types and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Primary Hyperoxaluria Drug (Value)
      • 5.2.1. Global Primary Hyperoxaluria Drug by: Type (Value)
        • 5.2.1.1. ALLN-230
        • 5.2.1.2. DCR-PHXC
        • 5.2.1.3. ALN-GO1
        • 5.2.1.4. Others
      • 5.2.2. Global Primary Hyperoxaluria Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Primary Hyperoxaluria Drug by: Drug types (Value)
        • 5.2.3.1. Primary hyperoxaluria type III (PH III)
        • 5.2.3.2. Primary hyperoxaluria type II (PH II)
        • 5.2.3.3. Primary hyperoxaluria type I (PH I)
      • 5.2.4. Global Primary Hyperoxaluria Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Primary Hyperoxaluria Drug (Volume)
      • 5.3.1. Global Primary Hyperoxaluria Drug by: Type (Volume)
        • 5.3.1.1. ALLN-230
        • 5.3.1.2. DCR-PHXC
        • 5.3.1.3. ALN-GO1
        • 5.3.1.4. Others
      • 5.3.2. Global Primary Hyperoxaluria Drug by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Others
      • 5.3.3. Global Primary Hyperoxaluria Drug by: Drug types (Volume)
        • 5.3.3.1. Primary hyperoxaluria type III (PH III)
        • 5.3.3.2. Primary hyperoxaluria type II (PH II)
        • 5.3.3.3. Primary hyperoxaluria type I (PH I)
      • 5.3.4. Global Primary Hyperoxaluria Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Primary Hyperoxaluria Drug (Price)
      • 5.4.1. Global Primary Hyperoxaluria Drug by: Type (Price)
  • 6. Primary Hyperoxaluria Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allena Pharmaceuticals Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alnylam Pharmaceuticals Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dicerna Pharmaceuticals Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Intellia Therapeutics Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. OxThera AB (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Primary Hyperoxaluria Drug Sale, by Type, Application, Drug types and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Primary Hyperoxaluria Drug (Value)
      • 7.2.1. Global Primary Hyperoxaluria Drug by: Type (Value)
        • 7.2.1.1. ALLN-230
        • 7.2.1.2. DCR-PHXC
        • 7.2.1.3. ALN-GO1
        • 7.2.1.4. Others
      • 7.2.2. Global Primary Hyperoxaluria Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Primary Hyperoxaluria Drug by: Drug types (Value)
        • 7.2.3.1. Primary hyperoxaluria type III (PH III)
        • 7.2.3.2. Primary hyperoxaluria type II (PH II)
        • 7.2.3.3. Primary hyperoxaluria type I (PH I)
      • 7.2.4. Global Primary Hyperoxaluria Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Primary Hyperoxaluria Drug (Volume)
      • 7.3.1. Global Primary Hyperoxaluria Drug by: Type (Volume)
        • 7.3.1.1. ALLN-230
        • 7.3.1.2. DCR-PHXC
        • 7.3.1.3. ALN-GO1
        • 7.3.1.4. Others
      • 7.3.2. Global Primary Hyperoxaluria Drug by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Others
      • 7.3.3. Global Primary Hyperoxaluria Drug by: Drug types (Volume)
        • 7.3.3.1. Primary hyperoxaluria type III (PH III)
        • 7.3.3.2. Primary hyperoxaluria type II (PH II)
        • 7.3.3.3. Primary hyperoxaluria type I (PH I)
      • 7.3.4. Global Primary Hyperoxaluria Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Primary Hyperoxaluria Drug (Price)
      • 7.4.1. Global Primary Hyperoxaluria Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Primary Hyperoxaluria Drug: by Type(USD Million)
  • Table 2. Primary Hyperoxaluria Drug ALLN-230 , by Region USD Million (2015-2020)
  • Table 3. Primary Hyperoxaluria Drug DCR-PHXC , by Region USD Million (2015-2020)
  • Table 4. Primary Hyperoxaluria Drug ALN-GO1 , by Region USD Million (2015-2020)
  • Table 5. Primary Hyperoxaluria Drug Others , by Region USD Million (2015-2020)
  • Table 6. Primary Hyperoxaluria Drug: by Application(USD Million)
  • Table 7. Primary Hyperoxaluria Drug Hospital , by Region USD Million (2015-2020)
  • Table 8. Primary Hyperoxaluria Drug Clinic , by Region USD Million (2015-2020)
  • Table 9. Primary Hyperoxaluria Drug Others , by Region USD Million (2015-2020)
  • Table 10. Primary Hyperoxaluria Drug: by Drug types(USD Million)
  • Table 11. Primary Hyperoxaluria Drug Primary hyperoxaluria type III (PH III) , by Region USD Million (2015-2020)
  • Table 12. Primary Hyperoxaluria Drug Primary hyperoxaluria type II (PH II) , by Region USD Million (2015-2020)
  • Table 13. Primary Hyperoxaluria Drug Primary hyperoxaluria type I (PH I) , by Region USD Million (2015-2020)
  • Table 14. South America Primary Hyperoxaluria Drug, by Country USD Million (2015-2020)
  • Table 15. South America Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 16. South America Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 17. South America Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 18. Brazil Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 19. Brazil Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 20. Brazil Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 21. Argentina Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 22. Argentina Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 23. Argentina Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 24. Rest of South America Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 27. Asia Pacific Primary Hyperoxaluria Drug, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 31. China Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 32. China Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 33. China Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 34. Japan Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 35. Japan Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 36. Japan Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 37. India Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 38. India Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 39. India Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 40. South Korea Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 41. South Korea Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 42. South Korea Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 43. Taiwan Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 44. Taiwan Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 45. Taiwan Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 46. Australia Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 47. Australia Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 48. Australia Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 52. Europe Primary Hyperoxaluria Drug, by Country USD Million (2015-2020)
  • Table 53. Europe Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 54. Europe Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 55. Europe Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 56. Germany Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 57. Germany Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 58. Germany Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 59. France Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 60. France Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 61. France Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 62. Italy Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 63. Italy Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 64. Italy Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 65. United Kingdom Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 68. Netherlands Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 69. Netherlands Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 70. Netherlands Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 71. Rest of Europe Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 74. MEA Primary Hyperoxaluria Drug, by Country USD Million (2015-2020)
  • Table 75. MEA Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 76. MEA Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 77. MEA Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 78. Middle East Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 79. Middle East Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 80. Middle East Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 81. Africa Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 82. Africa Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 83. Africa Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 84. North America Primary Hyperoxaluria Drug, by Country USD Million (2015-2020)
  • Table 85. North America Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 86. North America Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 87. North America Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 88. United States Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 89. United States Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 90. United States Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 91. Canada Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 92. Canada Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 93. Canada Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 94. Mexico Primary Hyperoxaluria Drug, by Type USD Million (2015-2020)
  • Table 95. Mexico Primary Hyperoxaluria Drug, by Application USD Million (2015-2020)
  • Table 96. Mexico Primary Hyperoxaluria Drug, by Drug types USD Million (2015-2020)
  • Table 97. Primary Hyperoxaluria Drug Sales: by Type(K Units)
  • Table 98. Primary Hyperoxaluria Drug Sales ALLN-230 , by Region K Units (2015-2020)
  • Table 99. Primary Hyperoxaluria Drug Sales DCR-PHXC , by Region K Units (2015-2020)
  • Table 100. Primary Hyperoxaluria Drug Sales ALN-GO1 , by Region K Units (2015-2020)
  • Table 101. Primary Hyperoxaluria Drug Sales Others , by Region K Units (2015-2020)
  • Table 102. Primary Hyperoxaluria Drug Sales: by Application(K Units)
  • Table 103. Primary Hyperoxaluria Drug Sales Hospital , by Region K Units (2015-2020)
  • Table 104. Primary Hyperoxaluria Drug Sales Clinic , by Region K Units (2015-2020)
  • Table 105. Primary Hyperoxaluria Drug Sales Others , by Region K Units (2015-2020)
  • Table 106. Primary Hyperoxaluria Drug Sales: by Drug types(K Units)
  • Table 107. Primary Hyperoxaluria Drug Sales Primary hyperoxaluria type III (PH III) , by Region K Units (2015-2020)
  • Table 108. Primary Hyperoxaluria Drug Sales Primary hyperoxaluria type II (PH II) , by Region K Units (2015-2020)
  • Table 109. Primary Hyperoxaluria Drug Sales Primary hyperoxaluria type I (PH I) , by Region K Units (2015-2020)
  • Table 110. South America Primary Hyperoxaluria Drug Sales, by Country K Units (2015-2020)
  • Table 111. South America Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 112. South America Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 113. South America Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 114. Brazil Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 115. Brazil Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 116. Brazil Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 117. Argentina Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 118. Argentina Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 119. Argentina Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 120. Rest of South America Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 121. Rest of South America Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 122. Rest of South America Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 123. Asia Pacific Primary Hyperoxaluria Drug Sales, by Country K Units (2015-2020)
  • Table 124. Asia Pacific Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 125. Asia Pacific Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 126. Asia Pacific Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 127. China Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 128. China Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 129. China Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 130. Japan Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 131. Japan Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 132. Japan Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 133. India Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 134. India Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 135. India Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 136. South Korea Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 137. South Korea Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 138. South Korea Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 139. Taiwan Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 140. Taiwan Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 141. Taiwan Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 142. Australia Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 143. Australia Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 144. Australia Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 146. Rest of Asia-Pacific Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 147. Rest of Asia-Pacific Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 148. Europe Primary Hyperoxaluria Drug Sales, by Country K Units (2015-2020)
  • Table 149. Europe Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 150. Europe Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 151. Europe Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 152. Germany Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 153. Germany Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 154. Germany Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 155. France Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 156. France Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 157. France Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 158. Italy Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 159. Italy Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 160. Italy Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 161. United Kingdom Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 162. United Kingdom Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 163. United Kingdom Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 164. Netherlands Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 165. Netherlands Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 166. Netherlands Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 167. Rest of Europe Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 168. Rest of Europe Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 169. Rest of Europe Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 170. MEA Primary Hyperoxaluria Drug Sales, by Country K Units (2015-2020)
  • Table 171. MEA Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 172. MEA Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 173. MEA Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 174. Middle East Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 175. Middle East Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 176. Middle East Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 177. Africa Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 178. Africa Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 179. Africa Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 180. North America Primary Hyperoxaluria Drug Sales, by Country K Units (2015-2020)
  • Table 181. North America Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 182. North America Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 183. North America Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 184. United States Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 185. United States Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 186. United States Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 187. Canada Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 188. Canada Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 189. Canada Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 190. Mexico Primary Hyperoxaluria Drug Sales, by Type K Units (2015-2020)
  • Table 191. Mexico Primary Hyperoxaluria Drug Sales, by Application K Units (2015-2020)
  • Table 192. Mexico Primary Hyperoxaluria Drug Sales, by Drug types K Units (2015-2020)
  • Table 193. Primary Hyperoxaluria Drug: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Primary Hyperoxaluria Drug: by Type(USD Million)
  • Table 200. Primary Hyperoxaluria Drug ALLN-230 , by Region USD Million (2021-2026)
  • Table 201. Primary Hyperoxaluria Drug DCR-PHXC , by Region USD Million (2021-2026)
  • Table 202. Primary Hyperoxaluria Drug ALN-GO1 , by Region USD Million (2021-2026)
  • Table 203. Primary Hyperoxaluria Drug Others , by Region USD Million (2021-2026)
  • Table 204. Primary Hyperoxaluria Drug: by Application(USD Million)
  • Table 205. Primary Hyperoxaluria Drug Hospital , by Region USD Million (2021-2026)
  • Table 206. Primary Hyperoxaluria Drug Clinic , by Region USD Million (2021-2026)
  • Table 207. Primary Hyperoxaluria Drug Others , by Region USD Million (2021-2026)
  • Table 208. Primary Hyperoxaluria Drug: by Drug types(USD Million)
  • Table 209. Primary Hyperoxaluria Drug Primary hyperoxaluria type III (PH III) , by Region USD Million (2021-2026)
  • Table 210. Primary Hyperoxaluria Drug Primary hyperoxaluria type II (PH II) , by Region USD Million (2021-2026)
  • Table 211. Primary Hyperoxaluria Drug Primary hyperoxaluria type I (PH I) , by Region USD Million (2021-2026)
  • Table 212. South America Primary Hyperoxaluria Drug, by Country USD Million (2021-2026)
  • Table 213. South America Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 214. South America Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 215. South America Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 216. Brazil Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 217. Brazil Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 218. Brazil Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 219. Argentina Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 220. Argentina Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 221. Argentina Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 222. Rest of South America Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 223. Rest of South America Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 224. Rest of South America Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 225. Asia Pacific Primary Hyperoxaluria Drug, by Country USD Million (2021-2026)
  • Table 226. Asia Pacific Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 227. Asia Pacific Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 228. Asia Pacific Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 229. China Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 230. China Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 231. China Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 232. Japan Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 233. Japan Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 234. Japan Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 235. India Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 236. India Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 237. India Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 238. South Korea Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 239. South Korea Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 240. South Korea Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 241. Taiwan Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 242. Taiwan Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 243. Taiwan Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 244. Australia Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 245. Australia Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 246. Australia Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 249. Rest of Asia-Pacific Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 250. Europe Primary Hyperoxaluria Drug, by Country USD Million (2021-2026)
  • Table 251. Europe Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 252. Europe Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 253. Europe Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 254. Germany Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 255. Germany Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 256. Germany Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 257. France Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 258. France Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 259. France Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 260. Italy Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 261. Italy Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 262. Italy Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 263. United Kingdom Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 264. United Kingdom Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 265. United Kingdom Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 266. Netherlands Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 267. Netherlands Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 268. Netherlands Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 269. Rest of Europe Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 270. Rest of Europe Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 271. Rest of Europe Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 272. MEA Primary Hyperoxaluria Drug, by Country USD Million (2021-2026)
  • Table 273. MEA Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 274. MEA Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 275. MEA Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 276. Middle East Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 277. Middle East Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 278. Middle East Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 279. Africa Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 280. Africa Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 281. Africa Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 282. North America Primary Hyperoxaluria Drug, by Country USD Million (2021-2026)
  • Table 283. North America Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 284. North America Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 285. North America Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 286. United States Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 287. United States Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 288. United States Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 289. Canada Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 290. Canada Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 291. Canada Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 292. Mexico Primary Hyperoxaluria Drug, by Type USD Million (2021-2026)
  • Table 293. Mexico Primary Hyperoxaluria Drug, by Application USD Million (2021-2026)
  • Table 294. Mexico Primary Hyperoxaluria Drug, by Drug types USD Million (2021-2026)
  • Table 295. Primary Hyperoxaluria Drug Sales: by Type(K Units)
  • Table 296. Primary Hyperoxaluria Drug Sales ALLN-230 , by Region K Units (2021-2026)
  • Table 297. Primary Hyperoxaluria Drug Sales DCR-PHXC , by Region K Units (2021-2026)
  • Table 298. Primary Hyperoxaluria Drug Sales ALN-GO1 , by Region K Units (2021-2026)
  • Table 299. Primary Hyperoxaluria Drug Sales Others , by Region K Units (2021-2026)
  • Table 300. Primary Hyperoxaluria Drug Sales: by Application(K Units)
  • Table 301. Primary Hyperoxaluria Drug Sales Hospital , by Region K Units (2021-2026)
  • Table 302. Primary Hyperoxaluria Drug Sales Clinic , by Region K Units (2021-2026)
  • Table 303. Primary Hyperoxaluria Drug Sales Others , by Region K Units (2021-2026)
  • Table 304. Primary Hyperoxaluria Drug Sales: by Drug types(K Units)
  • Table 305. Primary Hyperoxaluria Drug Sales Primary hyperoxaluria type III (PH III) , by Region K Units (2021-2026)
  • Table 306. Primary Hyperoxaluria Drug Sales Primary hyperoxaluria type II (PH II) , by Region K Units (2021-2026)
  • Table 307. Primary Hyperoxaluria Drug Sales Primary hyperoxaluria type I (PH I) , by Region K Units (2021-2026)
  • Table 308. South America Primary Hyperoxaluria Drug Sales, by Country K Units (2021-2026)
  • Table 309. South America Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 310. South America Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 311. South America Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 312. Brazil Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 313. Brazil Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 314. Brazil Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 315. Argentina Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 316. Argentina Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 317. Argentina Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 318. Rest of South America Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 319. Rest of South America Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 320. Rest of South America Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 321. Asia Pacific Primary Hyperoxaluria Drug Sales, by Country K Units (2021-2026)
  • Table 322. Asia Pacific Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 323. Asia Pacific Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 324. Asia Pacific Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 325. China Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 326. China Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 327. China Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 328. Japan Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 329. Japan Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 330. Japan Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 331. India Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 332. India Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 333. India Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 334. South Korea Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 335. South Korea Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 336. South Korea Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 337. Taiwan Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 338. Taiwan Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 339. Taiwan Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 340. Australia Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 341. Australia Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 342. Australia Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 343. Rest of Asia-Pacific Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 344. Rest of Asia-Pacific Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 345. Rest of Asia-Pacific Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 346. Europe Primary Hyperoxaluria Drug Sales, by Country K Units (2021-2026)
  • Table 347. Europe Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 348. Europe Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 349. Europe Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 350. Germany Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 351. Germany Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 352. Germany Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 353. France Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 354. France Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 355. France Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 356. Italy Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 357. Italy Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 358. Italy Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 359. United Kingdom Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 360. United Kingdom Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 361. United Kingdom Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 362. Netherlands Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 363. Netherlands Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 364. Netherlands Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 365. Rest of Europe Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 366. Rest of Europe Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 367. Rest of Europe Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 368. MEA Primary Hyperoxaluria Drug Sales, by Country K Units (2021-2026)
  • Table 369. MEA Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 370. MEA Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 371. MEA Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 372. Middle East Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 373. Middle East Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 374. Middle East Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 375. Africa Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 376. Africa Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 377. Africa Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 378. North America Primary Hyperoxaluria Drug Sales, by Country K Units (2021-2026)
  • Table 379. North America Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 380. North America Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 381. North America Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 382. United States Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 383. United States Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 384. United States Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 385. Canada Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 386. Canada Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 387. Canada Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 388. Mexico Primary Hyperoxaluria Drug Sales, by Type K Units (2021-2026)
  • Table 389. Mexico Primary Hyperoxaluria Drug Sales, by Application K Units (2021-2026)
  • Table 390. Mexico Primary Hyperoxaluria Drug Sales, by Drug types K Units (2021-2026)
  • Table 391. Primary Hyperoxaluria Drug: by Type(USD/Units)
  • Table 392. Research Programs/Design for This Report
  • Table 393. Key Data Information from Secondary Sources
  • Table 394. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Primary Hyperoxaluria Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Primary Hyperoxaluria Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Primary Hyperoxaluria Drug: by Drug types USD Million (2015-2020)
  • Figure 7. South America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 8. Asia Pacific Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 9. Europe Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 10. MEA Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 11. North America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 12. Global Primary Hyperoxaluria Drug: by Type K Units (2015-2020)
  • Figure 13. Global Primary Hyperoxaluria Drug: by Application K Units (2015-2020)
  • Figure 14. Global Primary Hyperoxaluria Drug: by Drug types K Units (2015-2020)
  • Figure 15. South America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 16. Asia Pacific Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 17. Europe Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 18. MEA Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 19. North America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 20. Global Primary Hyperoxaluria Drug: by Type USD/Units (2015-2020)
  • Figure 21. Global Primary Hyperoxaluria Drug share by Players 2020 (%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Allena Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Allena Pharmaceuticals Inc (United States) Revenue: by Geography 2020
  • Figure 25. Alnylam Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Alnylam Pharmaceuticals Inc (United States) Revenue: by Geography 2020
  • Figure 27. Dicerna Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. Dicerna Pharmaceuticals Inc (United States) Revenue: by Geography 2020
  • Figure 29. Intellia Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Intellia Therapeutics Inc (United States) Revenue: by Geography 2020
  • Figure 31. OxThera AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 32. OxThera AB (Sweden) Revenue: by Geography 2020
  • Figure 33. Global Primary Hyperoxaluria Drug: by Type USD Million (2021-2026)
  • Figure 34. Global Primary Hyperoxaluria Drug: by Application USD Million (2021-2026)
  • Figure 35. Global Primary Hyperoxaluria Drug: by Drug types USD Million (2021-2026)
  • Figure 36. South America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 37. Asia Pacific Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 38. Europe Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 39. MEA Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 40. North America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 41. Global Primary Hyperoxaluria Drug: by Type K Units (2021-2026)
  • Figure 42. Global Primary Hyperoxaluria Drug: by Application K Units (2021-2026)
  • Figure 43. Global Primary Hyperoxaluria Drug: by Drug types K Units (2021-2026)
  • Figure 44. South America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 45. Asia Pacific Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 46. Europe Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 47. MEA Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 48. North America Primary Hyperoxaluria Drug Share (%), by Country
  • Figure 49. Global Primary Hyperoxaluria Drug: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Allena Pharmaceuticals Inc (United States)
  • Alnylam Pharmaceuticals Inc (United States)
  • Dicerna Pharmaceuticals Inc (United States)
  • Intellia Therapeutics Inc (United States)
  • OxThera AB (Sweden)
Select User Access Type

Key Highlights of Report


Apr 2021 219 Pages 60 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Primary Hyperoxaluria Drug Quantitative research analysis
Global Primary Hyperoxaluria Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Primary Hyperoxaluria Drug market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Primary Hyperoxaluria Drug market are Allena Pharmaceuticals Inc (United States), Alnylam Pharmaceuticals Inc (United States), Dicerna Pharmaceuticals Inc (United States), Intellia Therapeutics Inc (United States) and OxThera AB (Sweden), to name a few.
In this highly competitive & fast evolving Primary Hyperoxaluria Drug industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Primary Hyperoxaluria Drug Report?

Have a Query? Click Here

Other Related Reports

Cancer Immunotherapies Comprehensive Study by End-User (Healthcare Sector, Pharmaceutical, Cancer Research Centre, Laboratory, Others), Cancer Type (Bladder Cancer, Brain Cancer, Cervical Cancer, Hea...
$ 3350
Central Venous Catheter Comprehensive Study by Type (Peripherally Inserted Central Venous Catheter, Tunneled Central Venous Catheter, Non-tunneled Central Venous Catheter), Application (Kidney Dialys...
$ 3750
Pancreatitis Drugs Comprehensive Study by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Drug Form (Tablets, Capsule), Pancreatitis (Acute Pancreatitis, Chronic Pancreatitis), End...
$ 3450
Glucomannan Extract Comprehensive Study by Type (Glucomannan 75%, Glucomannan 80%, Glucomannan 90%), Application (Food Industry, Pharmaceutical Industry, Healthy Products Industry), Form (Tablet, Pow...
$ 3450
Leuprolide Acetate Comprehensive Study by Type (Intramuscular, Subcutaneous), Application (Prostate Cancer, Precocious, Uterine Fibroid, Others) Players and Region - Global Market Outlook to 2027
$ 3500
Bromhexine Comprehensive Study by Application (Chronic Bronchitis, Asthma, Cough, Other), Form (Tablets, Syrup), Host (Oral, Injection), Dosage (48 mg/day, 96 mg/day, Others) Players and Region - Glo...
$ 3500